Please login to the form below

Not currently logged in
Email:
Password:

primary hyperoxaluria type 1

This page shows the latest primary hyperoxaluria type 1 news and features for those working in and with pharma, biotech and healthcare.

Alnylam’s third RNAi drug clears phase 3 trial in rare kidney disease

Alnylam’s third RNAi drug clears phase 3 trial in rare kidney disease

Lumasiran hits its objectives in the 20-patient phase 3 trial, which involved patients aged six and over with primary hyperoxaluria type 1 (PH1), a life-threatening but ultra-rare condition ... type 2 form (PH2) of the disease, which is caused by a

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Life Medicom

We are a fully integrated agency that is 100% dedicated to creating standout communications in healthcare. Our success starts by...

Latest intelligence

Understanding behaviour change: A Porterhouse Insights specialism
...
Robust Review: COVID19 Assessment
See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
Human behaviour - Sept 21
All change – how untangling human behaviour can encourage better health
Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...